Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.

Sarcoidosis%20-%20pulmonary Treatment

Principles of Therapy

  • Decision to treat sarcoidosis depends on the presence of symptoms & stage of the disease

Pulmonary Disease

  • Pulmonary disease is a relative indication for treatment

Stage 1

  • Studies show that no treatment is necessary for patients w/ stage 1 disease

Stage 2-3

  • Asymptomatic patients w/ stage 2 or 3 disease may not benefit from systemic therapy
    • Treatment may be required in asymptomatic patients w/ progressive loss of lung function & persistent infiltrates

Symptomatic Disease

  • Treatment w/ corticosteroids provides acute relief & reversal of organ dysfunction

Absolute Indications for Treatment of Sarcoidosis Include the following:

  • Cardiac involvement
  • Neurosarcoidosis
  • Hypercalcemia
  • Ocular disease that is refractory to topical therapy

Other Extra Pulmonary Diseases

  • Treatment is usually administered in progressive, symptomatic, extrapulmonary disease



Systemic Corticosteroids

  • The mainstay in the treatment of pulmonary sarcoidosis
  • Recommended for patients w/ hypercalcemia, stage II/III pulmonary sarcoidosis w/ moderate-severe or progressive disease, & those w/ radiographic evidence of pulmonary changes
  • Usually results in improvement of respiratory symptoms, lung function studies & CXR findings
    • Reappearance of symptoms & CXR abnormalities are frequent after discontinuation of treatment
  • A meta-analysis concluded that corticosteroid use in pulmonary sarcoidosis results in improvement of CXR & spirometry over 6-24 months, but there is minimal proof of improvement in lung function
    • It is not clear whether these improvements are maintained beyond 2 years
    • It is not known whether corticosteroids improve long-term pulmonary function or favorably alter disease progression
  • Corticosteroid use should be reserved for those w/ clear clinical indication because of its known potential toxicity & lack of evidence of sustained benefit

Follow-Up & Duration of Therapy

  • Patient should be evaluated after 1-3 months of corticosteroid therapy
    • Patients who fail to respond after 3 months are unlikely to respond to a longer course of therapy
  • Patients who respond should have their corticosteroid dosages tapered & treatment continued for a minimum of 12 months
  • After a treatment period of 6-24 months, withdrawal of corticosteroids should be considered, w/ continued monitoring for relapse
    • Certain patients may still require long-term low-dose therapy to prevent recurrent disease

Complications of Therapy

  • Patients receiving chronic corticosteroid therapy are at risk for osteoporosis
    • Bisphosphonates & Calcitonin may be used for prevention of osteoporosis complications

Inhaled Corticosteroids

  • An alternative to oral corticosteroids
  • May be used for patients w/ pulmonary symptoms especially chronic coughing, & for those whose systemic steroid medications are due for reduction/tapering
  • Studies show that patients experienced symptom improvement while on inhaled Budesonide treatment


  • Eg Azathioprine, Methotrexate, Cyclophosphamide, Chlorambucil, Cyclosporine, Leflunomide
  • May benefit patients who fail to respond to corticosteroids
  • Usually given in combination w/ corticosteroids but may also be used as monotherapy


  • Second-line treatment for sarcoidosis; as a corticosteroid-sparing agent
  • Preferred agent, along w/ Methotrexate, because of a more favorable safety profile
  • Usual dose: 50-100 mg daily initially, then up to 3 mg/kg daily as maintenance


  • Rarely used because of its increased risk of malignancy


  • Decreases lymphocyte proliferation & function thereby decreasing the immune response
  • Seldom used as 3rd-line treatment because of increased appearance of pancytopenia
  • Has been effective in some patients who have failed therapy w/ corticosteroids & Methotrexate
  • Significant toxicity limits its use in patients w/ severe, refractory disease


  • Recommended for patients w/ chronic sarcoidosis intolerant to Methotrexate therapy
  • May also be used in combination w/ Methotrexate in patients w/ chronic pulmonary sarcoidosis refractory to other therapies


  • Recommended as 1st-line treatment when in combination w/ steroids
  • Recommended 2nd-line treatment for steroid-refractory patients as a steroid-sparing agent
    • Used especially w/ the presence of adverse effects of corticosteroid therapy
  • Usual dose: 10 mg once a week initially, then 2.5-15 mg once a week as maintenance


  • 3rd-line treatment option for patients unresponsive to corticosteroids &/or immunosuppressants
  • Lacks evidence for the treatment of sarcoidosis
  • Adequate tests for presence of ongoing infection (eg latent tuberculosis) should be done prior to initiation of treatment

Tumor Necrosis Factor-Alpha (TNF-alpha) Inhibitors

  • Eg Infliximab, Adalimumab
  • Evidence to support Adalimumab’s efficacy for pulmonary chronic sarcoidosis are limited
  • Infliximab is used as an alternative pulmonary & extrapulmonary sarcoidosis therapy for patients refractory to corticosteroids
  • Studies show that Infliximab is an effective TNF-alpha inhibitor not only against pulmonary, but also for other types of sarcoidosis (ie skin, kidney, muscle, bone), & for patients w/ hypercalcemia, neuropathy & disabling fatigue


  • Further studies are needed to prove the efficacy of Etanercept therapy against sarcoidosis


  • Studies show that patients w/ acute pulmonary sarcoidosis respond well to Pentoxifylline


  • Studies proving the efficacy of Thalidomide for pulmonary sarcoidosis is lacking

Anti-malarial Agents

Chloroquine & Hydroxychloroquine

  • Action: May inhibit macrophage production of TNF-α
  • Efficacy for the treatment of chronic sarcoidosis has been established
  • Effect on disease activity is more likely suppressive than curative
  • Chloroquine has been shown to be particularly helpful in hypercalcemia & lupus pernio
  • Hydroxychloroquine is usually preferred because of lower risk of ocular toxicity
  • Usual dose:
    • Chloroquine: 500 mg daily initially then 250 mg daily as maintenance
    • Hydroxychloroquine: 200-400 mg daily
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.